Model-Based Benefit–Risk Assessment: Can Archimedes Help?
Copyright policy )Model-Based Benefit–Risk Assessment: Can Archimedes Help?
In December 2008, the US Food and Drug Administration issued a new draft Guidance for Industry on Diabetes Mellitus--evaluating cardiovascular risk in new antidiabetic therapies to treat Type 2 diabetes. This guidance comes at a time when recent discussions have focused on delineation of cardiovascular risk reduction for new antidiabetic drugs. Computational tools that can enable early prediction of cardiovascular risk are reviewed with specific reference to Archimedes (Kaiser Permanente), with an aim of proposing a model-based solution and enabling decisions to be made as early as possible in the drug development value chain.
- Merck & Co. United States
Diabetes Mellitus, Type 2, Cardiovascular Diseases, United States Food and Drug Administration, Advisory Committees, Humans, Hypoglycemic Agents, Models, Biological, Risk Assessment, United States
Diabetes Mellitus, Type 2, Cardiovascular Diseases, United States Food and Drug Administration, Advisory Committees, Humans, Hypoglycemic Agents, Models, Biological, Risk Assessment, United States
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).3 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average
Citations provided by BIP!Popularity provided by BIP!